{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:48:02Z","timestamp":1791488882297,"version":"4.3.4"},"reference-count":32,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T00:00:00Z","timestamp":1653609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Agency for Medical Research and Development (AMED)","award":["JP22fk0210075h0003"],"award-info":[{"award-number":["JP22fk0210075h0003"]}]},{"name":"AbbVie GK","award":["JP22fk0210075h0003"],"award-info":[{"award-number":["JP22fk0210075h0003"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hepatitis A virus (HAV) infection is a major cause of acute hepatitis worldwide and occasionally causes acute liver failure and can lead to death in the absence of liver transplantation. Although HAV vaccination is available, the prevalence of HAV vaccination is not adequate in some countries. Additionally, the improvements in public health reduced our immunity to HAV infection. These situations motivated us to develop potentially new anti-HAV therapeutic options. We carried out the in silico screening of anti-HAV compounds targeting the 3C protease enzyme using the Schrodinger Modeling software from the antiviral library of 25,000 compounds to evaluate anti-HAV 3C protease inhibitors. Additionally, in vitro studies were introduced to examine the inhibitory effects of HAV subgenomic replicon replication and HAV HA11-1299 genotype IIIA replication in hepatoma cell lines using luciferase assays and real-time RT-PCR. In silico studies enabled us to identify five lead candidates with optimal binding interactions in the active site of the target HAV 3C protease using the Schrodinger Glide program. In vitro studies substantiated our hypothesis from in silico findings. One of our lead compounds, Z10325150, showed 47% inhibitory effects on HAV genotype IB subgenomic replicon replication and 36% inhibitory effects on HAV genotype IIIA HA11-1299 replication in human hepatoma cell lines, with no cytotoxic effects at concentrations of 100 \u03bcg\/mL. The effects of the combination therapy of Z10325150 and RNA-dependent RNA polymerase inhibitor, favipiravir on HAV genotype IB HM175 subgenomic replicon replication and HAV genotype IIIA HA11-1299 replication showed 64% and 48% inhibitory effects of HAV subgenomic replicon and HAV replication, respectively. We identified the HAV 3C protease inhibitor Z10325150 through in silico screening and confirmed the HAV replication inhibitory activity in human hepatocytes. Z10325150 may offer the potential for a useful HAV inhibitor in severe hepatitis A.<\/jats:p>","DOI":"10.3390\/ijms23116044","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T01:40:45Z","timestamp":1653702045000},"page":"6044","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of Potential Anti-Hepatitis A Virus 3C Protease Inhibitors Using Molecular Docking"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2681-0776","authenticated-orcid":false,"given":"Reina","family":"Sasaki-Tanaka","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan C.","family":"Nagulapalli Venkata","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical and Administrative Sciences, Saint Louis College of Pharmacy, University of Health Sciences and Pharmacy, St. Louis, MO 63010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0827-0964","authenticated-orcid":false,"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4617-508X","authenticated-orcid":false,"given":"Mitsuhiko","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1654-5385","authenticated-orcid":false,"given":"Tatsuo","family":"Kanda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi-kamicho, Itabashi-ku, Tokyo 173-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1872-034X.2012.01009.x","article-title":"Hepatitis A, B, C and E virus markers in Chinese residing in Tokyo, Japan","volume":"42","author":"Yan","year":"2012","journal-title":"Hepatol. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3201\/eid1704.101169","article-title":"Hepatitis A virus vaccine escape variants and potential new serotype emergence","volume":"17","author":"Costafreda","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ebiom.2018.11.023","article-title":"Evidence for positive selection of hepatitis A virus antigenic variants in vaccinated men-having-sex-with men patients: Implications for immunization policies","volume":"39","author":"Gregori","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/CMR.19.1.63-79.2006","article-title":"Diagnosis of hepatitis A virus infection: A molecular approach","volume":"19","author":"Nainan","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1128\/jvi.65.11.5828-5838.1991","article-title":"The 5\u2032 nontranslated region of hepatitis A virus RNA: Secondary structure and elements required for translation in vitro","volume":"65","author":"Brown","year":"1991","journal-title":"J. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.bbrc.2005.03.105","article-title":"Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site","volume":"330","author":"Kanda","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1006\/viro.1994.1030","article-title":"Proteinase 3C of hepatitis A virus (HAV) cleaves the HAV polyprotein P2-P3 at all sites including VP1\/2A and 2A\/2B","volume":"198","author":"Schultheiss","year":"1994","journal-title":"Virology"},{"key":"ref_8","first-page":"618","article-title":"Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein","volume":"17","author":"Kanda","year":"2010","journal-title":"J. Viral Hepat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/369072a0","article-title":"Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases","volume":"369","author":"Allaire","year":"1994","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/viro.1999.9968","article-title":"Crystal structure of an inhibitor complex of the 3C proteinase from hepatitis A virus (HAV) and implications for the polyprotein processing in HAV","volume":"265","author":"Bergmann","year":"1999","journal-title":"Virology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jmb.2005.09.074","article-title":"Dual modes of modification of hepatitis A virus 3C protease by a serine-derived beta-lactone: Selective crystallization and formation of a functional catalytic triad in the active site","volume":"354","author":"Yin","year":"2005","journal-title":"J. Mol. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/febs.14707","article-title":"Toward development of generic inhibitors against the 3C proteases of picornaviruses","volume":"286","author":"Banerjee","year":"2019","journal-title":"FEBS J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.drudis.2020.12.005","article-title":"Potential SARS-CoV-2 main protease inhibitors","volume":"26","author":"Banerjee","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2174\/1568026621666210521164545","article-title":"Application of In silico Methods in the Design of Drugs for Neurodegenerative Diseases","volume":"21","author":"Haider","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/978-1-4939-7201-2_18","article-title":"Docking and Virtual Screening in Drug Discovery","volume":"1647","author":"Kontoyianni","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/cbdd.13764","article-title":"GWOVina: A grey wolf optimization approach to rigid and flexible receptor docking","volume":"97","author":"Wong","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Sasaki-Tanaka, R., Shibata, T., Okamoto, H., Moriyama, M., and Kanda, T. (2022). Favipiravir Inhibits Hepatitis A Virus Infection in Human Hepatocytes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052631"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1099\/0022-1317-83-9-2183","article-title":"Replication of a hepatitis A virus replicon detected by genetic recombination in vivo","volume":"83","author":"Kusov","year":"2002","journal-title":"J. Gen. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s43141-020-00066-2","article-title":"In silico design and molecular docking study of CDK2 inhibitors with potent cytotoxic activity against HCT116 colorectal cancer cell line","volume":"18","author":"Ikwu","year":"2020","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/hepr.13345","article-title":"Deteriorated outcome of recent patients with acute liver failure and late-onset hepatic failure caused by infection with hepatitis A virus: A subanalysis of patients seen between 1998 and 2015 and enrolled in nationwide surveys in Japan","volume":"49","author":"Nakao","year":"2019","journal-title":"Hepatol. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.vaccine.2021.03.012","article-title":"Safety and immunogenicity of inactivated hepatitis\u2014A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study","volume":"39","author":"Susarla","year":"2021","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jhep.2021.04.035","article-title":"Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990\u20132019","volume":"75","author":"Zeng","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.14218\/JCTH.2015.00016","article-title":"Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus","volume":"3","author":"Kanda","year":"2015","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir Plus Ritonavir: First Approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3855\/jidc.14485","article-title":"Antivirals against HCV infection: The story thus far","volume":"16","author":"Irekeola","year":"2022","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejmech.2019.02.048","article-title":"New 4-phenylcoumarin derivatives as potent 3C protease inhibitors: Design, synthesis, anti-HAV effect and molecular modeling","volume":"168","author":"Kassem","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18970","DOI":"10.1038\/s41598-021-98529-0","article-title":"Synthesis, delivery, and molecular docking of fused quinolines as inhibitor of Hepatitis A virus 3C proteinase","volume":"11","author":"Jorshari","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.bmcl.2019.04.043","article-title":"Anti-HAV evaluation and molecular docking of newly synthesized 3-benzyl(phenethyl)benzo[g]quinazolines","volume":"29","author":"Anouar","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Jiang, X., Kanda, T., Wu, S., Nakamoto, S., Saito, K., Shirasawa, H., Kiyohara, T., Ishii, K., Wakita, T., and Okamoto, H. (2014). Suppression of La antigen exerts potential antiviral effects against hepatitis A virus. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101993"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijfoodmicro.2007.01.017","article-title":"Evaluation of an extracting method for the detection of Hepatitis A virus in shellfish by SYBR-Green real-time RT-PCR","volume":"120","author":"Casas","year":"2007","journal-title":"Int. J. Food Microbiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/11\/6044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:20:06Z","timestamp":1760138406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/11\/6044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,27]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["ijms23116044"],"URL":"https:\/\/doi.org\/10.3390\/ijms23116044","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,27]]}}}